Status:
UNKNOWN
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
Lead Sponsor:
Tanta University
Conditions:
Covid19
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,
Detailed Description
The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,
Eligibility Criteria
Inclusion
- COVID 19 positive patients
Exclusion
- COVID-19 patients with critical manifestations.
- Sepsis.
- Acute respiratory distress syndrome (ARDS).
- Decompensated liver disease (Child-Pugh class B or C disease).
- Chronic renal impairment.
- Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….).
- Ischemic heart disease within the last 6 months.
- Chronic pulmonary disease.
- Malignancy.
- Pregnancy or breastfeeding.
- Hypersensitivity to sofosbuvir or ribavirin.
- Patients with organ transplant.
- Unwilling to participate in our study
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 10 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04497649
Start Date
July 1 2020
End Date
April 10 2021
Last Update
December 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo and Tanta Universitities
Tanta, Egypt